Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €65.40 EUR
Change Today -0.89 / -1.34%
Volume 43.1K
ADOC On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
Frankfurt
As of 11:39 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

adocia sas (ADOC) Snapshot

Open
€66.10
Previous Close
€66.29
Day High
€66.35
Day Low
€65.00
52 Week High
02/6/15 - €75.50
52 Week Low
08/1/14 - €12.36
Market Cap
447.5M
Average Volume 10 Days
103.7K
EPS TTM
--
Shares Outstanding
6.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADOCIA SAS (ADOC)

Related News

No related news articles were found.

adocia sas (ADOC) Related Businessweek News

No Related Businessweek News Found

adocia sas (ADOC) Details

Adocia, a biotechnology company, develops medicines from therapeutic proteins. The company focuses on insulin therapy and the treatment of diabetic foot ulcer based on its BioChaperone technological platform. Its product pipeline includes BioChaperone PDGF-BB, which is in Phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone insulin that is in Phase II clinical trials, as well as in pre clinical stage for the treatment of diabetes; and Driveln, which is preclinical stage for the treatment of oncology. The company, through its collaboration partnerships with pharmaceutical companies, also develops formulations for monoclonal antibodies. Adocia Société Anonyme was founded in 2005 and is based in Lyon, France.

74.6 Employees
Last Reported Date: 05/6/15
Founded in 2005

adocia sas (ADOC) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €280.0K
Co-Founder, Vice-President, Director of Resea...
Total Annual Compensation: €191.4K
Compensation as of Fiscal Year 2013.

adocia sas (ADOC) Key Developments

Adocia and Eli Lilly Report Positive Phase 1b Topline Results on the Post-Meal Effect of Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes

Adocia and Eli Lilly and Company announced the completion of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia’s proprietary technology BioChaperone, which is designed to accelerate insulin absorption. This completed study, part of the Adocia-Lilly partnership, aimed to compare the effects of BioChaperone Lispro and Humalog® (insulin lispro rDNA origin) when injected at mealtime on post-prandial glycemic control in type 1 diabetes patients. While commercialized fast-acting insulin analogs are injected five to 15 minutes before or immediately after a meal, an ultra-rapid insulin may allow injection at the time of the meal, or even after the start of a meal while improving post-prandial glycemic control. In this crossover, randomized, double-blind meal study, 38 people with type 1 diabetes received a 0.2 U/kg dose of either BioChaperone Lispro or Humalog just prior to a standardized meal. The primary endpoint was a comparison of the post-meal glycemic excursions over the first two hours (Delta-AUC-BG(0-2h)). BioChaperone Lispro was associated with a 61% reduction in post-prandial glucose excursion over the first two hours compared to Humalog (Delta-AUC-BG(0-2h) ratio = 0.39; 95%-CI 0.28 to 0.52; p<0.0001). The study also provides confirmation of the ultra-rapid pharmacokinetic profile of BioChaperone Lispro. These results are consistent with previous clinical findings from NCT021466511 demonstrating BioChaperone Lispro has a significantly faster rate of insulin lispro absorption than Humalog with an increase in the early insulin exposure of 168% at the same dose (AUClispro_0-30min ratio = 2.68; 95%-CI 2.18 to 3.30; p<0.0001). In terms of safety, BioChaperone Lispro and Humalog led to similar numbers of hypoglycemia episodes. No local reactions were seen on the site of administration for either treatment.

Adocia Société Anonyme(ENXTPA:ADOC) added to SBF 120 Index

Adocia Société Anonyme has been added to SBF 120 Index.

Adocia Société Anonyme(ENXTPA:ADOC) dropped from CAC Small Index

Adocia Société Anonyme will be removed from CAC Small Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADOC:FP €65.40 EUR -0.89

ADOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADOC.
View Industry Companies
 

Industry Analysis

ADOC

Industry Average

Valuation ADOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 89.7x
Price/Book 149.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 86.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADOCIA SAS, please visit www.adocia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.